Preliminary characterization of N-trimethylchitosan as a nanocarrier for malaria vaccine

P. O. Nnamani, G. Scoles, S. Kröl

Research output: Contribution to journalArticlepeer-review


Background & objectives: With the current snags from the use of Artemisinin-combination therapies (ACTs) in malaria treatment in addition to fear of cross-resistance to unrelated drugs, raising the immunocompetence of individuals in malaria endemic areas by vaccination is the best approach to malaria-free world. Methods: Water-soluble cationic derivative, N, N, N-trimethylchitosan (TMC) was synthesized from chitosan. Nanoparticles of the TMC were prepared in various media [milliQ water, Na2CO3 (pH 10.92), Na2HPO4 (PBS, pH 9.01 and alhydrogel®] which were characterized as adjuvants for possible vaccine delivery. The nanoparticles were characterized for particle size, surface charge and morphology using microscopy (Phase contrast microscope and Confocal laser scanning microscope), and Malvern zetasizer Nano-ZS. Time-resolved particle size analysis was performed after one month storage of the TMC nanoparticles at 4°C. Results: The result of the study showed that PBS was the best medium that produced cationic, monodispersed and stable TMC nanoparticles of

Original languageEnglish
Pages (from-to)224-230
Number of pages7
JournalJournal of Vector Borne Diseases
Issue number4
Publication statusPublished - Dec 2011


  • Alhydrogel®
  • Malaria
  • N-trimethylchitosan
  • Nanocarrier
  • PBS
  • Vaccine

ASJC Scopus subject areas

  • Infectious Diseases
  • Parasitology


Dive into the research topics of 'Preliminary characterization of N-trimethylchitosan as a nanocarrier for malaria vaccine'. Together they form a unique fingerprint.

Cite this